| Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic … SL James, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ... The Lancet 392 (10159), 1789-1858, 2018 | 8807 | 2018 |
| The ATLAS simulation infrastructure ATLAS Collaboration atlas. secretariat@ cern. ch, G Aad, B Abbott, ... The European Physical Journal C 70 (3), 823-874, 2010 | 8161 | 2010 |
| Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of … GA Roth, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ... The lancet 392 (10159), 1736-1788, 2018 | 6681 | 2018 |
| Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and … JD Stanaway, A Afshin, E Gakidou, SS Lim, D Abate, KH Abate, ... The Lancet 392 (10159), 1923-1994, 2018 | 5830* | 2018 |
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis SR Nalluri, D Chu, R Keresztes, X Zhu, S Wu Jama 300 (19), 2277-2285, 2008 | 962 | 2008 |
| Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 D Dicker, G Nguyen, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ... The lancet 392 (10159), 1684-1735, 2018 | 956 | 2018 |
| Measurement of the azimuthal anisotropy for charged particle production in TeV lead-lead collisions with the ATLAS detector G Aad, B Abbott, J Abdallah, SA Khalek, AA Abdelalim, A Abdesselam, ... Physical Review C 86 (1), 014907, 2012 | 924 | 2012 |
| Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis X Zhu, S Wu, WL Dahut, CR Parikh American Journal of Kidney Diseases 49 (2), 186-193, 2007 | 777 | 2007 |
| Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis V Ranpura, S Hapani, S Wu Jama 305 (5), 487-494, 2011 | 530 | 2011 |
| Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic … R Lozano, N Fullman, D Abate, SM Abay, C Abbafati, N Abbasi, ... The lancet 392 (10159), 2091-2138, 2018 | 496 | 2018 |
| Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis S Hapani, D Chu, S Wu The lancet oncology 10 (6), 559-568, 2009 | 491 | 2009 |
| Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis S Wu, JJ Chen, A Kudelka, J Lu, X Zhu The lancet oncology 9 (2), 117-123, 2008 | 477 | 2008 |
| Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor VR Belum, B Benhuri, MA Postow, MD Hellmann, AM Lesokhin, NH Segal, ... European journal of cancer 60, 12-25, 2016 | 433 | 2016 |
| Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib ME Lacouture, S Wu, C Robert, MB Atkins, HH Kong, J Guitart, C Garbe, ... The oncologist 13 (9), 1001-1011, 2008 | 413 | 2008 |
| Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis X Zhu, K Stergiopoulos, S Wu Acta oncologica 48 (1), 9-17, 2009 | 382 | 2009 |
| Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials V Ranpura, S Hapani, J Chuang, S Wu Acta oncologica 49 (3), 287-297, 2010 | 338 | 2010 |
| Measurement of underlying event characteristics using charged particles in collisions at and 7 TeV with the ATLAS detector G Aad, B Abbott, J Abdallah, AA Abdelalim, A Abdesselam, B Abi, ... Physical Review D 83 (11), 112001, 2011 | 336 | 2011 |
| Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 CJL Murray, CSKH Callender, XR Kulikoff, V Srinivasan, D Abate, ... The Lancet 392 (10159), 1995-2051, 2018 | 286 | 2018 |
| Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis V Ranpura, B Pulipati, D Chu, X Zhu, S Wu American journal of hypertension 23 (5), 460-468, 2010 | 286 | 2010 |
| The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance CA Lazarski, FA Chaves, SA Jenks, S Wu, KA Richards, JM Weaver, ... Immunity 23 (1), 29-40, 2005 | 269 | 2005 |
James L. GulleyNational Cancer InstituteVerified email at mail.nih.gov
